J. Ferlay, E. Steliarova-foucher, J. Lortet-tieulent, S. Rosso, J. Coebergh et al., Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012, Eur J Cancer Oxf Engl, vol.49, issue.6, pp.1374-403, 1990.

, Projection de l'incidence et de la mortalité par cancer en France métropolitaine en, Maladies chroniques et traumatismes / Rapports et synthèses / Publications et outils / Accueil [Internet, 2017.

D. Sur,

G. Defossez, Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre, 1990.

D. Hoffmann and I. Hoffmann, The changing cigarette, 1950-1995, J Toxicol Environ Health. mars, vol.50, issue.4, pp.307-64, 1997.

A. Jemal, E. Ward, and M. Thun, Declining death rates reflect progress against cancer, PloS One. 9 mars, vol.5, issue.3, p.9584, 2010.

F. Barlesi, P. Tomasini, C. Fournier, and L. Greillier, Présentation clinique et diagnostic du cancer bronchique, Rev Mal Respir Actual. sept, vol.6, issue.4, pp.341-346, 2014.

D. Debieuvre, C. Locher, A. Neidhardt, F. Goupil, B. Lemaire et al., Évolution en 10 ans du cancer bronchique non à petites cellules en fonction du sexe, 2014.

D. Sur,

. Has and . Santé, Cancers broncho-pulmonaires. Les parcours de Soins/ Juillet 2013 / Service des maladies chroniques et dispositifs d'accompagnement des malades -INCa/ Département Diffusion des bonnes pratiques et information des malades

P. Goldstraw, K. Chansky, J. Crowley, R. Rami-porta, H. Asamura et al., The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. janv, vol.11, issue.1, pp.39-51, 2016.

E. Wd-t, . Hk-m-h, and . Cc-h, Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart, Report-Series/Who-Iarc-Classification-Of-Tumours/Pathology-And-Genetics-Of-Tumours-Of-The-Lung-Pleura-Thymus-And-Heart, 2004.

G. Defossez, L. Guyader-peyrou, S. Uhry, Z. Grosclaude, P. Colonna et al., Synthèse Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre, 1990.

W. Pao and N. Girard, New driver mutations in non-small-cell lung cancer, Lancet Oncol. févr, vol.12, issue.2, pp.175-80, 2011.

M. Reck, D. Rodríguez-abreu, A. G. Robinson, R. Hui, T. Cs?szi et al., Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.10, issue.19, pp.1823-1856, 2016.

N. A. Rizvi, M. D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov et al., Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science. 3 avr, vol.348, issue.6230, pp.124-132, 2015.

F. A. Shepherd, J. Crowley, P. Van-houtte, P. E. Postmus, D. Carney et al., The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. déc, vol.2, issue.12, pp.1067-77, 2007.

P. Goldstraw, J. Crowley, K. Chansky, D. J. Giroux, P. A. Groome et al., The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. août, vol.2, issue.8, pp.706-720, 2007.

R. Rami-porta, V. Bolejack, J. Crowley, D. Ball, J. Kim et al., The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. juill, vol.10, issue.7, pp.990-1003, 2015.

H. Asamura, K. Chansky, J. Crowley, P. Goldstraw, V. W. Rusch et al., The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. déc, vol.10, issue.12, pp.1675-84, 2015.

W. Eberhardt, A. Mitchell, J. Crowley, H. Kondo, Y. T. Kim et al., The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, vol.10, issue.11, pp.1515-1537, 2015.

G. Chassagnon, S. Bennani, and M. Revel, Nouvelle classification TNM des cancers du poumon non à petites cellules. /data/revues/07618417/v73i1/S0761841716301559, 2017.

D. Sur,

, comité de rédaction de l'édition 2019. Accueil Cancers pneumologiques | Ressources/ Référentiels Auvergne Rhône-Alpes en oncologie thoracique

R. A. Ressources, , 2019.

G. A. Silvestri, M. K. Gould, M. L. Margolis, L. T. Tanoue, D. Mccrory et al., Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines, Chest. sept, vol.132, issue.3, pp.178-201, 2007.

R. M. Pieterman, J. Van-putten, J. J. Meuzelaar, E. L. Mooyaart, W. Vaalburg et al., Preoperative Staging of Non-Small-Cell Lung Cancer with Positron-Emission Tomography, N Engl J Med. 27 juill, vol.343, issue.4, pp.254-61, 2000.

F. Soumia, A. Leila, R. Mohamed, H. Laila, E. Mustapha et al., F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment, Pan Afr Med J [Internet, vol.4, issue.2017, pp.886-95, 2001.

, Tomographie par émission de positons et amélioration de la survie de patients porteurs de carcinome bronchique : l'effet Will Rogers revisité -EM|consulte

D. Sur,

D. Planchard, S. Popat, K. Kerr, S. Novello, E. F. Smit et al., Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up ?, Ann Oncol, vol.29, issue.Supplement_4, pp.192-237, 2018.

M. Pérol, A. Swalduz, V. Paulus, and V. Avrillon, Chimiothérapie de première ligne incluant le traitement de maintenance et les anti-angiogéniques dans les CBNPC avancés en l'absence d'addiction oncogénique, Rev Mal Respir Actual. oct, vol.10, issue.3, pp.369-79, 2018.

G. V. Scagliotti, P. Parikh, J. Von-pawel, B. Biesma, J. Vansteenkiste et al., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol Off J Am Soc Clin Oncol. 20 juill, vol.26, issue.21, pp.3543-51, 2008.

J. Soria, Y. Ohe, J. Vansteenkiste, T. Reungwetwattana, B. Chewaskulyong et al., Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer, N Engl J Med, vol.11, issue.2, pp.113-138, 2018.

S. Peters, D. R. Camidge, A. T. Shaw, S. Gadgeel, J. S. Ahn et al., Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.31, issue.9, pp.829-867, 2017.

D. Planchard, B. Besse, H. Groen, P. Souquet, E. Quoix et al., Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial, Lancet Oncol. juill, vol.17, issue.7, pp.984-93, 2016.

L. Gandhi, D. Rodríguez-abreu, S. Gadgeel, E. E. Felip, E. et al., Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N Engl J Med. 31 mai, vol.378, issue.22, pp.2078-92, 2018.

R. S. Herbst, P. Baas, D. Kim, E. Felip, J. L. Pérez-gracia et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet Lond Engl. 9 avr, vol.387, pp.1540-50, 2016.

J. Brahmer, K. L. Reckamp, P. Baas, L. Crinò, W. Eberhardt et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med. 9 juill, vol.373, issue.2, pp.123-158, 2015.

A. Rittmeyer, F. Barlesi, D. Waterkamp, K. Park, F. Ciardiello et al., Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet Lond Engl, vol.21, pp.255-65, 2017.

S. J. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami et al., Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer, N Engl J Med, vol.16, issue.20, pp.1919-1948, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01753457

L. Gust, G. Brioude, N. Ghourchidian, S. Dizier, A. Charvet et al., Stratégie chirurgicale : quelles nouvelles techniques ? La chirurgie minimalement invasive (RATS/VATS). Les exérèses d'épargne parenchymateuse. Les parcours de soin accélérés, Rev Mal Respir Actual. sept, vol.9, issue.2, pp.161-71, 2017.

H. Yang, K. M. Woo, C. S. Sima, M. S. Bains, P. S. Adusumilli et al., Long-term Survival Based on the Surgical Approach to Lobectomy For Clinical Stage I Nonsmall Cell Lung Cancer: Comparison of Robotic, Video-assisted Thoracic Surgery, and Thoracotomy Lobectomy, Ann Surg, vol.265, issue.2, pp.431-438, 2017.

J. A. Howington, M. G. Blum, A. C. Chang, A. A. Balekian, and S. C. Murthy, Treatment of stage I and II nonsmall cell lung cancer: Diagnosis and management of lung cancer, Chest. mai, vol.143, issue.5, pp.278-313, 2013.

R. K. Bindal, R. Sawaya, M. E. Leavens, K. R. Hess, and S. H. Taylor, Reoperation for recurrent metastatic brain tumors, J Neurosurg. oct, vol.83, issue.4, pp.600-604, 1995.

G. Al-shamy and R. Sawaya, Management of brain metastases: the indispensable role of surgery, J Neurooncol. mai, vol.92, issue.3, pp.275-82, 2009.

A. N. Patel, C. B. Simone, and S. K. Jabbour, Risk factors and management of oligometastatic non-small cell lung cancer, Ther Adv Respir Dis. août, vol.10, issue.4, pp.338-386, 2016.

M. Dellaretti, N. Reyns, F. Dubois, G. Touzet, E. Lartigau et al., Traitement des métastases cérébrales par radiochirurgie Gamma Knife: à propos de 115 patients, vol.29, 2008.

D. Sur,

E. A. Monaco, R. Grandhi, A. Niranjan, and L. D. Lunsford, The past, present and future of Gamma Knife radiosurgery for brain tumors: the Pittsburgh experience, Expert Rev Neurother. avr, vol.12, issue.4, pp.437-482, 2012.

J. C. Flickinger, D. Kondziolka, L. D. Lunsford, R. J. Coffey, M. L. Goodman et al., A multiinstitutional experience with stereotactic radiosurgery for solitary brain metastasis, Int J Radiat Oncol Biol Phys. 1 mars, vol.28, issue.4, pp.797-802, 1994.

A. C. Tree, V. S. Khoo, R. A. Eeles, M. Ahmed, D. P. Dearnaley et al., Stereotactic body radiotherapy for oligometastases, Lancet Oncol. janv, vol.14, issue.1, pp.28-37, 2013.

M. Motta, A. Vecchio, L. Attuati, P. Picozzi, L. Perna et al., Gamma knife radiosurgery for treatment of cerebral metastases from non-small-cell lung cancer, Int J Radiat Oncol Biol Phys, vol.15, issue.4, pp.463-468, 2011.

M. Gerosa, A. Nicolato, R. Foroni, L. Tomazzoli, and A. Bricolo, Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery, J Neurosurg. janv, vol.102, pp.75-80, 2005.

R. Fuentes, D. Osorio, E. Hernandez, J. Simancas-racines, D. Martinez-zapata et al., Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis, Cochrane Database Syst Rev, vol.20, p.12086, 2018.

P. Károlyi, Do adrenal metastases from lung cancer develop by lymphogenous or hematogenous route?, J Surg Oncol, vol.43, issue.3, pp.154-160, 1990.

J. Blay and R. E. Métastases, John Libbey Eurotext, vol.106, 2015.

C. A. Klein, Parallel progression of primary tumours and metastases, Nat Rev Cancer, vol.9, issue.4, pp.302-314, 2009.

E. R. Fearon and B. Vogelstein, A genetic model for colorectal tumorigenesis, Cell. 1 juin, vol.61, issue.5, pp.759-67, 1990.

A. Desmet, P. Van-schil, and P. Van-houtte, Quelles stratégies thérapeutiques pour les CBNPC oligométastatiques ?, Rev Mal Respir Actual. oct, vol.10, issue.3, pp.326-357, 2018.

S. Paget, The distribution of secondary growths in cancer of the breast. 1889, Cancer Metastasis Rev. août, vol.8, issue.2, pp.98-101, 1989.

G. P. Gupta and J. Massagué, Cancer metastasis: building a framework, Cell, vol.127, issue.4, pp.679-95, 2006.

R. R. Weichselbaum and S. Hellman, Oligometastases revisited, Nat Rev Clin Oncol, vol.8, issue.6, pp.378-82, 2011.

S. Hellman, R. R. Weichselbaum, and . Oligometastases, J Clin Oncol Off J Am Soc Clin Oncol. janv, vol.13, issue.1, pp.8-10, 1995.

Y. Niibe and J. Y. Chang, Novel insights of oligometastases and oligo-recurrence and review of the literature, Pulm Med, p.261096, 2012.

A. B. Ashworth, S. Senan, D. A. Palma, M. Riquet, Y. C. Ahn et al., An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic nonsmall-cell lung cancer, Clin Lung Cancer. sept, vol.15, issue.5, pp.346-55, 2014.

D. A. Palma, J. K. Salama, S. S. Lo, S. Senan, T. Treasure et al., The oligometastatic stateseparating truth from wishful thinking, Nat Rev Clin Oncol, vol.11, issue.9, pp.549-57, 2014.

W. Ouyang, J. Yu, S. Nuerjiang, Z. Li, D. Wang et al., Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer, Cancer Med. 27 juin, 2019.

Y. Shi, J. Yang, N. Yao, M. Shao, W. Ding et al., Factors Affecting the Survival of Patients with Oligometastatic Non-Small-Cell Lung Cancer: A Meta-Analysis, Can Respir J, 2019.

K. E. Rusthoven, B. D. Kavanagh, S. H. Burri, C. Chen, H. Cardenes et al., Multiinstitutional phase I/II trial of stereotactic body radiation therapy for lung metastases, J Clin Oncol Off J Am Soc Clin Oncol. 1 avr, vol.27, issue.10, pp.1579-84, 2009.

M. T. Milano, A. W. Katz, A. G. Muhs, A. Philip, D. J. Buchholz et al., A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions, Cancer. 1 févr, vol.112, issue.3, pp.650-658, 2008.

K. E. Rusthoven, B. D. Kavanagh, H. Cardenes, V. W. Stieber, S. H. Burri et al., Multiinstitutional phase I/II trial of stereotactic body radiation therapy for liver metastases, J Clin Oncol Off J Am Soc Clin Oncol. 1 avr, vol.27, issue.10, pp.1572-1580, 2009.

M. Dahele, A. Brade, S. Pearson, and A. Bezjak, Stereotactic radiation therapy for inoperable, earlystage non-small-cell lung cancer, CMAJ Can Med Assoc J. 23 juin, vol.180, issue.13, pp.1326-1334, 2009.

J. Wu, H. Li, R. Shekhar, M. Suntharalingam, D. Souza et al., An evaluation of planning techniques for stereotactic body radiation therapy in lung tumors, Radiother Oncol J Eur Soc Ther Radiol Oncol. avr, vol.87, issue.1, pp.35-43, 2008.

G. Kantor, J. J. Mazeron, F. Mornex, and P. Maingon, Volume tumoral macroscopique (GTV) et volumecible anatomoclinique (CTV) en radiothérapie. /data/revues/12783218/v0005i05/01001317

D. Sur,

R. Wiggenraad, A. Verbeek-de-kanter, H. B. Kal, M. Taphoorn, T. Vissers et al., Doseeffect relation in stereotactic radiotherapy for brain metastases. A systematic review, Radiother Oncol J Eur Soc Ther Radiol Oncol. mars, vol.98, issue.3, pp.292-299, 2011.

P. W. Sperduto, T. J. Yang, K. Beal, H. Pan, P. D. Brown et al., Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA), JAMA Oncol. 1 juin, vol.3, issue.6, pp.827-858, 2017.

A. Gunjur, C. Duong, D. Ball, and S. Siva, Surgical and ablative therapies for the management of adrenal « oligometastases » -A systematic review, Cancer Treat Rev. août, vol.40, issue.7, pp.838-884, 2014.

T. Tanvetyanon, L. A. Robinson, M. J. Schell, V. E. Strong, R. Kapoor et al., Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis, J Clin Oncol Off J Am Soc Clin Oncol. 1 mars, vol.26, issue.7, pp.1142-1149, 2008.

G. Dupic, J. Biau, A. Bellière-calandry, and M. Lapeyre, Radiothérapie stéréotaxique hypofractionnée des métastases surrénaliennes. Cancer/Radiothérapie, vol.21, pp.404-414, 2017.

W. W. Chance, Q. Nguyen, R. Mehran, J. W. Welsh, D. R. Gomez et al., Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity, Pract Radiat Oncol. juin, vol.7, issue.3, pp.195-203, 2017.

R. H. Mole, Whole body irradiation; radiobiology or medicine?, Br J Radiol. mai, vol.26, issue.305, pp.234-275, 1953.

K. Reynders, T. Illidge, S. Siva, J. Y. Chang, D. Ruysscher et al., The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant, Cancer Treat Rev. juin, vol.41, issue.6, pp.503-513, 2015.

J. P. Nesseler, D. Peiffert, G. Vogin, P. Nickers, and . Cancer, , vol.10

D. Sur,

Y. Lee, S. L. Auh, Y. Wang, B. Burnette, Y. Wang et al., Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment, Blood. 16 juill, vol.114, issue.3, pp.589-95, 2009.

J. M. Bauml, R. Mick, C. Ciunci, C. Aggarwal, C. Davis et al., Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial, JAMA Oncol. 11 juill, 2019.

U. S. Department, . Health, . Human, and . Services, National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute, Disponible sur: Published, 2009.

E. Ippolito, D. 'angelillo, R. M. Fiore, M. Molfese, E. Trodella et al., SBRT: A viable option for treating adrenal gland metastases, Rep Pract Oncol Radiother, vol.20, issue.6, pp.484-90, 2015.

T. De-vin, B. Engels, T. Gevaert, G. Storme, D. Ridder et al., Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival, Ann Oncol Off J Eur Soc Med Oncol. févr, vol.25, issue.2, pp.467-71, 2014.

D. R. Gomez, C. Tang, J. Zhang, G. R. Blumenschein, M. Hernandez et al., Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study, J Clin Oncol Off J Am Soc Clin Oncol. 20 juin, vol.37, issue.18, pp.1558-65, 2019.

D. De-ruysscher, R. Wanders, A. Van-baardwijk, A. Dingemans, B. Reymen et al., Radical Treatment of Non-Small-Cell Lung Cancer Patients with Synchronous Oligometastases: Long-Term Results of a Prospective Phase II Trial (Nct01282450), J Thorac Oncol, vol.7, issue.10, pp.1547-55, 2012.

S. Li, R. Zhu, D. Li, N. Li, and X. Zhu, Prognostic factors of oligometastatic non-small cell lung cancer: a meta-analysis, J Thorac Dis. juin, vol.10, issue.6, pp.3701-3714, 2018.

D. R. Gomez, G. R. Blumenschein, J. J. Lee, M. Hernandez, R. Ye et al., Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study, Lancet Oncol. déc, vol.17, issue.12, pp.1672-82, 2016.

P. Iyengar, Z. Wardak, D. E. Gerber, V. Tumati, C. Ahn et al., Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial, JAMA Oncol. 11 janv, vol.4, issue.1, p.173501, 2018.

G. Rodrigues, W. Eppinga, F. Lagerwaard, P. De-haan, C. Haasbeek et al., A pooled analysis of arc-based image-guided simultaneous integrated boost radiation therapy for oligometastatic brain metastases, Radiother Oncol J Eur Soc Ther Radiol Oncol. févr, vol.102, issue.2, pp.180-186, 2012.

L. Guerra, J. L. Gomez, D. Zhuang, Y. Hong, D. S. Heymach et al., Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis, Int J Radiat Oncol Biol Phys. 1 sept, vol.84, issue.1, pp.61-67, 2012.

E. Rrc-grand,

, Réseau régional de cancérologie

D. R. Gomez, Y. Niibe, and J. Y. Chang, Oligometastatic disease at presentation or recurrence for nonsmall cell lung cancer, Pulm Med, p.396592, 2012.

L. E. Hendriks, J. L. Derks, P. E. Postmus, R. A. Damhuis, R. Houben et al., Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study, Eur J Cancer Oxf Engl, vol.51, issue.17, pp.2534-2578, 1990.

P. Bonnette, P. Puyo, C. Gabriel, R. Giudicelli, J. F. Regnard et al., Surgical management of non-small cell lung cancer with synchronous brain metastases, Chest. mai, vol.119, issue.5, pp.1469-75, 2001.

S. Collaud, R. Stahel, I. Inci, S. Hillinger, D. Schneiter et al., Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage, Lung Cancer Amst Neth. déc, vol.78, issue.3, pp.234-242, 2012.

S. Salah, T. Tanvetyanon, and S. Abbasi, Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases: systematic review and analysis of reported cases, Lung Cancer Amst Neth. janv, vol.75, issue.1, pp.9-14, 2012.

T. Inoue, N. Katoh, H. Aoyama, R. Onimaru, H. Taguchi et al., Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions, Jpn J Clin Oncol. août, vol.40, issue.8, pp.788-94, 2010.

C. Villarreal-garza, D. De-la-mata, D. G. Zavala, E. O. Macedo-perez, and O. Arrieta, Aggressive treatment of primary tumor in patients with non-small-cell lung cancer and exclusively brain metastases, Clin Lung Cancer. janv, vol.14, issue.1, pp.6-13, 2013.

A. Calles, X. Liao, L. M. Sholl, S. J. Rodig, G. J. Freeman et al., Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. déc, vol.10, issue.12, pp.1726-1761, 2015.

A. D'incecco, M. Andreozzi, V. Ludovini, E. Rossi, A. Capodanno et al., PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients, Br J Cancer. 6 janv, vol.112, issue.1, pp.95-102, 2015.

T. Shukuya and D. P. Carbone, Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, vol.11, issue.7, pp.976-88, 2016.

G. Bowden, H. Kano, E. Caparosa, S. Park, A. Niranjan et al., Gamma knife radiosurgery for the management of cerebral metastases from non-small cell lung cancer, J Neurosurg. avr, vol.122, issue.4, pp.766-72, 2015.

M. Yamamoto, T. Serizawa, T. Shuto, A. Akabane, Y. Higuchi et al., Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study, Lancet Oncol. avr, vol.15, issue.4, pp.387-95, 2014.

C. Collen, N. Christian, D. Schallier, M. Meysman, M. Duchateau et al., Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients, Ann Oncol Off J Eur Soc Med Oncol, vol.25, issue.10, pp.1954-1963, 2014.

J. E. Lodeweges, T. J. Klinkenberg, J. F. Ubbels, H. Groen, J. A. Langendijk et al., Long-term Outcome of Surgery or Stereotactic Radiotherapy for Lung Oligometastases, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, vol.12, issue.9, pp.1442-1447, 2017.

M. Niglas and P. Cheung, Ablative therapy in oligometastatic non-small cell lung cancer-an editorial on recent evidence, J Thorac Dis. janv, vol.10, issue.1, pp.138-178, 2018.

, Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer -Full Text View -ClinicalTrials.gov